Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Título

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Autor

Marco Bruno Luigi Rocchi, Luca Cantini, Lucia Bastianelli, Alessio Lupi, Giada Pinterpe, Federica Pecci, Giovanni Belletti, Rosa Stoico, Francesca Vitarelli, Marco Moretti, Nicoletta Onori, Riccardo Giampieri, Rossana Berardi

Descripción

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs.

Fecha

2021

Materia

seroprevalence, covid-19, Cancer patients, SARS-CoV-2–specific antibodies

Identificador

10.3390/jcm10071503

Fuente

Epidemiology and Health

Editor

Korean Society of Epidemiology

Cobertura

Medicine

Archivos

https://socictopen.socict.org/files/to_import/pdfs/13dc22dcd0729d767a8e47e2f1595c78.pdf

Colección

Citación

Marco Bruno Luigi Rocchi, Luca Cantini, Lucia Bastianelli, Alessio Lupi, Giada Pinterpe, Federica Pecci, Giovanni Belletti, Rosa Stoico, Francesca Vitarelli, Marco Moretti, Nicoletta Onori, Riccardo Giampieri, Rossana Berardi, “Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy,” SOCICT Open, consulta 28 de abril de 2026, https://socictopen.socict.org/items/show/6890.

Formatos de Salida

Position: 20393 (12 views)